Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | FFAR2 | O15552 | 5/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 4/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | WNT1 | P04628 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2277128 | 0.86 | MAPK1 (0.43) | PDPK1HTR6KDRWNT1GSK3B | |
| SCHEMBL2750989 | 0.82 | PDPK1 (0.46) | PDPK1FFAR2HTR6KDRBRD4 | |
| SCHEMBL2752575 | 0.81 | PDPK1 (0.46) | PDPK1FFAR2HTR6KDRBRD4 | |
| SCHEMBL2281187 | 0.80 | IRAK4 (0.37) | PDPK1WNT1GSK3BDYRK1ABRD4 | |
| SCHEMBL2752309 | 0.80 | PDPK1 (0.46) | PDPK1FFAR2HTR6KDRBRD4 | |
| SCHEMBL2283400 | 0.80 | PDPK1 (0.42) | PDPK1HTR6WNT1GSK3BDYRK1A | |
| SCHEMBL2277123 | 0.79 | TYRO3 (0.39) | PDPK1WNT1GSK3BDYRK1ABRD4 | |
| SCHEMBL12406850 | 0.79 | KDR (0.37) | ATRTDP1KDRMAPK1 | |
| SCHEMBL2752312 | 0.79 | PDPK1 (0.41) | PDPK1FFAR2PTGS2HTR6KDR | |
| SCHEMBL2277448 | 0.78 | PDPK1 (0.37) | PDPK1HTR6WNT1GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195951-A1 | DIAZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-08-11 | — | — | US | disclosed |
| US-20110195951-A1 | DIAZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-08-11 | — | — | US | disclosed |
| US-20110195951-A1 | DIAZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-08-11 | — | — | US | disclosed |
| WO-2010015803-A1 | DIAZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R & D MANAGEMENT CO. LTD (JP) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195951-A1 | DIAZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | DAPK1, DAPK2, DAPK3 | PDPK1 115/4885ATR 360/4885FFAR2 1817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.